Product Details
| Product Name: Clindamycin phosphate | CAS No.: 24729-96-2 |
| EC-No.: 246-433-0 | Min. Order: 1kg |
| Purity: 99% | Supply Ability: 100kg |
| Release date: 2025/12/13 |
Items | Specifications | Results |
Appearance | White to off-white crystalline powder | White crystalline powder |
Identification | IR:Meets the requirements | Conform |
HPLC:retention time conforms to RS | Conform | |
Crystallinity | Conform | Conform |
PH | 3.5~4.5 | 4.0 |
Water | ≤ 6.0% | 0.41% |
Assay | ≥758μg/mg clindamycin on the anhydrous substance | 836μg/mg |
Organic Impurities | Lincomycin phosphate ≤1.0% | 0.049% |
Lincomycin ≤0.5% | N.D. | |
Clindamycin B phosphate ≤1.5% | 0.053% | |
7-Epiclindamycin phosphate ≤0.8% | 0.21% | |
Clindamycin 3-phosphate ≤0.3% | N.D. | |
Clindamycin ≤0.5% | N.D. | |
Any indivdual,unspecified impurity ≤1.0% | N.D. | |
Total impurities ≤4.0% | 0.31% | |
Residual solvents | Methanol ≤3000ppm | 0.3 |
Ethanol ≤5000ppm | 580ppm | |
Acetone ≤5000ppm | N.D. | |
Conclusion | The product conforms to the above specifications. | |
Clindamycin Phosphate: Overview & Uses
Clindamycin phosphate is a water-soluble prodrug ester of the antibiotic clindamycin. It is inactive until converted by enzymes in the body into biologically active clindamycin.
Class: Lincosamide antibiotic.
Key Advantage: The phosphate ester form allows for parenteral administration (injection) and topical formulation, as it is much more soluble than clindamycin base.
Mechanism of Action
Once converted to active clindamycin, it works by binding to the 50S subunit of the bacterial ribosome. This inhibits bacterial protein synthesis, preventing bacteria from growing and multiplying (it is primarily bacteriostatic).
Primary Uses & Applications
1. Topical Formulations (Most Common Use):
Acne Vulgaris: A first-line topical treatment for inflammatory acne (gels, lotions, foams). Often combined with benzoyl peroxide.
Bacterial Vaginitis: Used as a vaginal cream or suppository.
Skin Infections: Topical solutions for minor bacterial skin infections.
2. Parenteral (Injectable) Formulations:
Used for serious systemic infections caused by anaerobic bacteria and certain gram-positive aerobes, including:
Severe Skin & Soft Tissue Infections (e.g., abscesses, cellulitis).
Intra-abdominal Infections (often mixed anaerobic/aerobic).
Pelvic Inflammatory Disease (PID).
Bone & Joint Infections.
As an alternative for patients allergic to penicillin.
3. Oral Form (Clindamycin HCl):
For similar systemic infections when oral therapy is appropriate.
Important Warnings & Side Effects
Clostridioides difficile-Associated Diarrhea (CDAD): A major risk. Can cause severe, potentially fatal colitis. Use is reserved for cases where benefits outweigh risks.
Allergy: Contraindicated in patients with hypersensitivity to clindamycin or lincomycin.
Spectrum: Primarily targets anaerobic bacteria and gram-positive cocci (e.g., Staphylococcus aureus, streptococci). NOT effective against gram-negative bacilli.
Prescription Only: Requires medical supervision.
Key Summary Table
| Feature | Description |
|---|---|
| What it is | A soluble prodrug of the antibiotic clindamycin. |
| Main Mechanism | Inhibits bacterial protein synthesis (bacteriostatic). |
| Topical Uses | Acne vulgaris, bacterial vaginosis, minor skin infections. |
| Systemic (IV/IM/Oral) Uses | Serious anaerobic & gram-positive infections (skin, abdomen, bone, pelvis). |
| Critical Warning | High risk of causing C. difficile colitis (severe diarrhea). |
| Availability | Prescription-only, in topical (gel, lotion, cream), vaginal, and injectable forms. |
Disclaimer: This information is for educational purposes. Clindamycin is a potent antibiotic with significant risks and must be used only under the direction of a healthcare professional.



Company Profile Introduction
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $48.00/100mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-12-10 | |
| $48.00/100mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-12-10 | |
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $0.00/10mg |
VIP2Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2025-03-20 | |
| $150.00/1kg |
Hebei Zhuanglai Chemical Trading Co Ltd
|
2024-11-26 | ||
| $0.00/1g |
VIP2Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-11-08 | |
| $10.00/1KG |
VIP7Y
|
Hebei Chuanghai Biotechnology Co., Ltd
|
2024-11-04 | |
| $100.00/50kg |
VIP2Y
|
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
|
2024-08-13 | |
| $0.00/25kg |
PUSHAN INDUSTRIAL (SHAANXI) CO.,LTD
|
2024-05-17 | ||
| $15.00/1kg |
Ouhuang Engineering Materials (Hubei) Co., Ltd
|
2024-04-28 |
- Since: 2006-04-03
- Address: Room 2015, No.2 Building Kaixin Mansion, No.107 Jinqiao Ave, Wuhan, China
+8613986145403
info@fortunachem.com

China